April 14, 2022 7:30am

Skim in anticipation of a coming depreciation in this market and resulting sector as expectation is an insecure factor

Pre-open indications: 9 SELLs into Strength, 2 Maintaining SELL and 1 Pimp/Pump/Promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are UP +0.18% (+62 points), S&P futures are UP +0.01% (+1 points) and NASDAQ futures are UP +0.06% (+19 points) early in the pre-open


Stock futures were positive in early premarket trade on Thursday morning as investors awaited quarterly earnings results from some of the biggest U.S. banks,

European markets were treading lightly as to the European Central Bank’s will announce its latest policy decision and developments in Ukraine,

Asia-Pacific markets were mostly higher as investors reacted to monetary policy tightening announcements by central banks in South Korea and Singapore.



The Dow closed UP +344.23points (+1.01%); the S&P closed UP +49.14 points (+1.12%) while the Nasdaq closed UP +272.02 points (+2.03%)

Economic Data Docket: retail sales, import prices and jobless claims are all set to come out at 8:30 a.m.


Last night’s RegMed Investors’ (RMi) closing bell post: “indexes up, sector positive after a six sessions dive, thank God we can rely on being oversold’s algorithmic response. On Thursday, the holiday-shortened week will end this week’s session.” … https://www.regmedinvestors.com/articles/12387

Ebb and flow –

Q2/22 – 2 positive and 6 negative close


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS, POSSIBILITIES and POTENTIALS …

SELL into Strength:

Alnylam Pharmaceuticals (ALNY) closed up +$8.88 or +5.56% to $168.46 with a positive +$0.89 or +0.53% pre-open indication.

Beam Therapeutics (BEAM) closed up +$1.45 to $51.52 after Tuesday’s +$1.06 with a positive +$1.48 or +2.87% pre-open indication after the equity hit an all-time low of $50.00 and a Broad Institute and win of a patent CPISPR challenge.

CRISPR Therapeutics (CRSP) closed up +$1.29 to $65.84 after Tuesday’s +$3.10 with a positive +$0.15 or -0.23% pre-open indication.

Chinook Therapeutics (KDNY) closed up +$0.63 or +4.15% to $15.81 with a positive +$0.79 or +5% pre-open indication.

Fate Therapeutics (FATE) closed up +$1.99 or 5.39% to $38.93 with a negative -$0.81 or -2.08% pre-open indication.

Regenxbio (RGNX) closed up +$0.86 or +2.84% to $31.11 with a positive +$0.24 or +0.77% pre-open indication.

Sage Therapeutics (SAGE) closed up +$1.00 or +2.86% to $35.97 with a positive +$0.39 or +1.08% pre-open indication.

uniQure NV (QURE) closed up +$1.50 or +8.06% to $20.11 with a positive =$0.67 or +1.84% pre-open indication.

Voyager Therapeutics (VYGR) closed up +$0.67 or +8.32% to $8.72 with a positive +$0.37 or +1.84% pre-open indication.


Maintaining SELL into Strength:

Intellia Therapeutics (NTLA) closed up +$1.65 to $63.00 after Tuesday’s -$0.32 with a negative -$0.02 or -0.03% pre-open indication

Global Blood Therapeutics (GBT)closed up +$1.06 to $36.07 after Tuesday’s +$0.97 with a negative -$0.44 or -1.22% pre-open indication.


Pimp/Pump and Promote:

Biostage (BSTG) closed up +$0.50 with 2,851 shares traded after Tuesday’s -$0.30 with 1,634 shares traded, Monday’s flat with 25 shares traded, Friday’s +$0.50 with 3,139 shares traded and last Thursday’s -$0.63 to $5.30.

  • WARNING:  WHY BUY this equity with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a precarious financial position dependent on a possible cash infusion? Also, WHY the pump of the volume to gain share appreciation – they have to reverse the multiple private placements (the priciest was $4.71) for a potential/proposed stock offering.


The BOTTOM LINE: Dramatic sector appreciation after a walloping, becomes quite suspect as news pricing lacks support.

State the obvious, investors are NOT in control of daily market driven sector appreciation or downward dives.

I try to keep it simple …

“The stock market rally rebounded Wednesday, paring weekly losses. The Dow Jones and S&P 500 index reclaimed their 50-day lines, but are below their 200-day averages. The Nasdaq and Russell 2000 are still below their 50-day lines, though the small-cap index is getting close. Even with their 2% gains, the Nasdaq and Russell 2000 had inside days vs. Tuesday's range. Meanwhile, NYSE and Nasdaq volume fell vs. Tuesday, after two straight distribution days.” <IBD>

I am still holding-on to the realization that the sector will POP for the grossly oversold; however, we are getting close to Q2 reporting season … yet, I can’t write away my misgivings about the daily missives. 

To expect a payday; volatility and low volume are part of the equation.

I am still, in the here and now, the cell and gene therapy sector will be on hold until clinical results stimulate these equities!

As I had stated, “Draining liquidity has impeded any shares pricing expectation.” I am also more than worried about pricey valuations that (in my mind’s eye) have NO basis.

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Share pricing intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.